Navigation Links
Freeslate’s Biologics Formulation System Selected by Sanofi Pasteur to Improve Efficiency of Formulation Development

Sunnyvale, Calif. (PRWEB) August 21, 2013

Freeslate, Inc., the leading provider of high throughput research solutions, today announced that Sanofi Pasteur, the vaccines division of Sanofi, has purchased Freeslate’s Biologics Formulation System, a comprehensive solution for accelerating research in vaccine and protein formulation development. The system automates sample preparation, sample stressing, and formulation analysis, allowing for the development of stable, robust formulations significantly faster with reduced API consumption.

Based on the Freeslate Core Module 3 (CM3) automation platform, the Biologics Formulation System combines liquid dispense and controlled heating/cooling/mixing with new automated measurements of pH, viscosity, and particle counting. Integrated by Freeslate’s Lab Execution and Analysis (LEA) software suite, the system provides intuitive experiment design and allows for the control and data integration of a range of third party analytics including Dynamic Light Scatter (DLS), UV/VIS plate readers, and High Pressure Liquid Chromatography (HPLC), maximizing R&D productivity.

“We are excited to be selected by a global leader in vaccines and are pleased they recognize the value our tools bring to the advancement of formulation development,” said John S. Senaldi, President and CEO of Freeslate. “As demonstrated by the adoption of our systems in Europe and across the globe, combinatorial approaches to vaccine formulation development can significantly accelerate productivity.”

Freeslate has built strong capabilities around automated solutions addressing the complex problems of drug development. The company’s products enable customers to better manage capacity by performing and assessing formulations, minimize later stage reformulations by exploring a broader analytical space early in development, and manage data from orthogonal analytics to help drive informed decision making.

About Freeslate

Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, and energy industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BiologicsMD, Inc. Announces Issuance of First U.S. Patent for PTH-CBD™
2. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
3. Synthetic Biologics to Report Second Quarter 2013 Financial Results
4. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
5. Synthetic Biologics to Present at OneMedForum New York 2013
6. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
7. Predictive Biomarker Discovery for Oncology Small-Molecules and Biologics - a Webinar Hosted by Xtalks
8. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
9. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
10. As the life science industry evolves, it is clear that biologics are here to stay!
11. Seminar Spotlights Key Trends in Biologics and Biosimilars
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today announced ... Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology ...
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Halozyme Therapeutics, Inc. ... Healthcare Conference in New York on Wednesday, ... Helen Torley , president and CEO, will provide a corporate ... New York at 1:00 p.m. ET/10:00 a.m. PT ... and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
Breaking Biology Technology:
(Date:11/18/2015)... PHILADELPHIA , Nov. 18, 2015  As new ... in children, doctors and other healthcare providers face challenges ... counsel families and patients. In addition, as more children ... into a patient,s adulthood and old age. ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... Paris from 17 th until ... from 17 th until 19 th November ... has invented the first combined scanner in the world which scans ... Until now two different scanners were required: one for passports ... on the same surface. This innovation is an ideal solution ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
Breaking Biology News(10 mins):